Table. 4—

Clinical success rates summarised for pathogens of primary interest# at the post-therapy visit in clinically evaluable patients

PathogenUncomplicatedComplicated
Levo.Azithro.Levo.Amox./clav.
Haemophilus influenzae27/27 (100)22/24 (91.7)25/30 (83.3)19/20 (95.0)
Haemophilus parainfluenzae19/20 (95.0)22/23 (95.7)17/20 (85.0)15/18 (83.3)
Moraxella catarrhalis14/14 (100)18/20 (90.0)11/12 (91.7)16/19 (84.2)
Streptococcus pneumoniae12/12 (100)9/11 (81.8)16/18 (88.9)9/13 (69.2)
Pseudomonas aeruginosa3/3 (100)5/6 (83.3)2/5 (40.0)4/5 (80.0)
Staphylococcus aureus7/7 (100)1/2 (50.0)4/5 (80.0)3/5 (60.0)
Klebsiella pneumoniae2/2 (100)5/6 (83.3)1/2 (50.0)4/5 (80.0)
Enterobacter cloacae1/1 (100)3/5 (60.0)0/0 (0.0)0/0 (0.0)
  • Data are presented as n/N patients who had the pathogen alone or in combination with other pathogens at study entry (%), unless otherwise stated. Levo.: levofloxacin; azithro.: azithromycin; amox.: amoxicillin; clav.: clavulanate. #: isolated from at least five patients.